“P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY: E.M. Piella1, A.M. Chiarandon1, V. Batti1, D.A. Montisano2, L. F. Iannone3, C. Fasano4, G. Sebastianelli5, G. Coppola5, D. Ferrandi6, C. Lanni7, M.P. Prudenzano8, M. De Tommaso9, P. Merlo10, A. Viganò10, F. De Cesaris11, A. Chiarugi11, A. Munafò11, F. Pistoia12, R. Ornello12, S. Sacco12, A. Doretti13, L. Grazzi2, F. Lo Castro14, R. Allamprese14, R. De Icco15|16, G. Vaghi15|16, C. Tassorelli15|16, G. Avino17, M. Romozzi18, C. Vollono18, P. Calabresi18, S. Battistini19, A. Rufa19, M. Albanese20, M. Trimboli21, G. Carlucci4, M. Silvestro22, A. Russo22, M. Valente23, L. Fofi24, M. Marcosano24, P. Geppetti25, C. Altamura24, F. Vernieri24, E. Rubino1, I. Rainero1, S. Guerzoni14 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Italy; 2Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 3Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; 4NEUROFARBA Department, University of Florence - Neurologia, AOU Careggi, Italy; 5Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; 6AOU Alessandria, SC Neurologia, Italy; 7Psicologia AOU Alessandria, Italy; 8Clinica Neurologica ‘L. Amaducci’, Azienda Ospedaliero-Universitaria Consorziale di Bari, Italy; 9Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Italy; 10UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; 11Headache center and Clinical pharmacology unit, AOU Careggi, Florence, Italy; 12Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 13Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; 14Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico, Modena, Italy; 15Department of Brain and Behavioral Sciences, University of Pavia, Italy; 16Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy; 17SOC Neurologia, Ospedale di Prato, Italy; 18Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 19Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; 20Unit of Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Italy; 21Headache Center, Unit of Neurology, AOU Renato Dulbecco, Catanzaro, Italy; 22Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Advanced Medical and Surgical Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy; 23DMED, University of Udine and Clinical Neurology, Udine University Hospital, Italy; 24Fondazione Policlinico Universitario Campus Bio-Medico, Roma e Università Campus Bio-Medico di Roma, Italy; 25Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, USA” (2026) Confinia Cephalalgica, 36(s1). doi:10.4081/cc.2026.15988.